Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced that CEO Roni Mamluk will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference, available on-demand from January 11, 2021, at 6:00 am ET. The presentation will provide insights into Ayala's focus on developing small molecule therapeutics for rare and aggressive cancers. The company is advancing two product candidates, AL101 and AL102, which target Notch pathway activation. AL101 holds Fast Track and Orphan Drug Designations from the FDA and is currently in Phase 2 trials for various cancers.

REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting Monday, January 11, 2021 at 6:00 am ET.

A live webcast of the presentation may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of the webcast will be available on the website for 90 days following the presentations.

About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). Ayala’s lead product candidate, AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. For more information, visit www.ayalapharma.com.

Contacts:

Investors:
Julie Seidel
Stern Investor Relations, Inc.
+1-212-362-1200
Julie.seidel@sternir.com

Ayala Pharmaceuticals:
+1-857-444-0553
info@ayalapharma.com

FAQ

What will Ayala Pharmaceuticals present at the H.C. Wainwright Bioconnect 2021 Conference?

Ayala Pharmaceuticals will present insights into its small molecule therapeutics for rare and aggressive cancers.

When can I watch the Ayala Pharmaceuticals presentation from the Bioconnect 2021 Conference?

The presentation will be available on-demand starting January 11, 2021, at 6:00 am ET.

What are the product candidates under development by Ayala Pharmaceuticals?

Ayala is developing AL101 and AL102, targeting the Notch pathway to treat various cancers.

What designations has AL101 received from the U.S. FDA?

AL101 has received both Fast Track Designation and Orphan Drug Designation from the FDA.

Which cancers are being targeted by AL101 in clinical trials?

AL101 is in Phase 2 trials for Adenoid Cystic Carcinoma and Triple Negative Breast Cancer.